Cargando…
A Novel Observational Method for Assessing Acute Responses to Cannabis: Preliminary Validation Using Legal Market Strains
Background: The development of novel cannabis research methods that are compatible with current federal regulations is imperative to conduct studies of the effects of legal market cannabis. There is very little research on higher strength, higher Δ9-tetrahydrocannabinol (THC), which has become incre...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870063/ https://www.ncbi.nlm.nih.gov/pubmed/29607409 http://dx.doi.org/10.1089/can.2017.0038 |
_version_ | 1783309402680328192 |
---|---|
author | Bidwell, L. Cinnamon Mueller, Raeghan YorkWilliams, Sophie L. Hagerty, Sarah Bryan, Angela D. Hutchison, Kent E. |
author_facet | Bidwell, L. Cinnamon Mueller, Raeghan YorkWilliams, Sophie L. Hagerty, Sarah Bryan, Angela D. Hutchison, Kent E. |
author_sort | Bidwell, L. Cinnamon |
collection | PubMed |
description | Background: The development of novel cannabis research methods that are compatible with current federal regulations is imperative to conduct studies of the effects of legal market cannabis. There is very little research on higher strength, higher Δ9-tetrahydrocannabinol (THC), which has become increasingly available since legalization. Research on strains containing cannabidiol (CBD), a second primary, but nonpsychotomimetic, cannabinoid, is very limited. Materials and Methods: Using a novel observational methodology, regular cannabis users were asked to use one of two legal market cannabis strains that they purchased from a local dispensary (one strain containing 8% THC and 16% CBD (THC+CBD) and one containing a 17% THC concentration, but no CBD (THC). After using their suggested cannabis strain as they typically would for a 3-day period, participants returned to the laboratory immediately after their final use. Measures included a blood draw to measure cannabinoid blood levels and circulating cytokines, self-reported subjective drug effects, and verbal recall memory. Results: Analysis of CBD/THC concentration levels in the blood following the 3-day strain manipulation suggests that all, but one participant (n=23/24) followed instructions and used their assigned strain. Individuals in the THC group (n=11) smoked no more than their usual amount, and participants who used the THC+CBD (n=12) strain smoked more than their reported usual amount, but did not have significantly different THC+metabolite blood levels from the THC group. The THC+CBD strain was also associated with less desire to smoke, lower levels of subjective drug effects, and lower levels of circulating cytokines (TNF-α, IL-6, and IL-1β) immediately after use. Conclusions: Initial results support the feasibility of this novel observational methodology involving brief manipulation of strain use. Preliminary findings indicate that participants may self-titrate cannabis use based on cannabinoid concentration and the THC+CBD strain was associated with lower levels of cannabis craving, subjective intoxication, and circulating cytokines. |
format | Online Article Text |
id | pubmed-5870063 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Mary Ann Liebert, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-58700632018-03-30 A Novel Observational Method for Assessing Acute Responses to Cannabis: Preliminary Validation Using Legal Market Strains Bidwell, L. Cinnamon Mueller, Raeghan YorkWilliams, Sophie L. Hagerty, Sarah Bryan, Angela D. Hutchison, Kent E. Cannabis Cannabinoid Res Original Research Background: The development of novel cannabis research methods that are compatible with current federal regulations is imperative to conduct studies of the effects of legal market cannabis. There is very little research on higher strength, higher Δ9-tetrahydrocannabinol (THC), which has become increasingly available since legalization. Research on strains containing cannabidiol (CBD), a second primary, but nonpsychotomimetic, cannabinoid, is very limited. Materials and Methods: Using a novel observational methodology, regular cannabis users were asked to use one of two legal market cannabis strains that they purchased from a local dispensary (one strain containing 8% THC and 16% CBD (THC+CBD) and one containing a 17% THC concentration, but no CBD (THC). After using their suggested cannabis strain as they typically would for a 3-day period, participants returned to the laboratory immediately after their final use. Measures included a blood draw to measure cannabinoid blood levels and circulating cytokines, self-reported subjective drug effects, and verbal recall memory. Results: Analysis of CBD/THC concentration levels in the blood following the 3-day strain manipulation suggests that all, but one participant (n=23/24) followed instructions and used their assigned strain. Individuals in the THC group (n=11) smoked no more than their usual amount, and participants who used the THC+CBD (n=12) strain smoked more than their reported usual amount, but did not have significantly different THC+metabolite blood levels from the THC group. The THC+CBD strain was also associated with less desire to smoke, lower levels of subjective drug effects, and lower levels of circulating cytokines (TNF-α, IL-6, and IL-1β) immediately after use. Conclusions: Initial results support the feasibility of this novel observational methodology involving brief manipulation of strain use. Preliminary findings indicate that participants may self-titrate cannabis use based on cannabinoid concentration and the THC+CBD strain was associated with lower levels of cannabis craving, subjective intoxication, and circulating cytokines. Mary Ann Liebert, Inc. 2018-03-01 /pmc/articles/PMC5870063/ /pubmed/29607409 http://dx.doi.org/10.1089/can.2017.0038 Text en © L. Cinnamon Bidwell et al. 2018; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Research Bidwell, L. Cinnamon Mueller, Raeghan YorkWilliams, Sophie L. Hagerty, Sarah Bryan, Angela D. Hutchison, Kent E. A Novel Observational Method for Assessing Acute Responses to Cannabis: Preliminary Validation Using Legal Market Strains |
title | A Novel Observational Method for Assessing Acute Responses to Cannabis: Preliminary Validation Using Legal Market Strains |
title_full | A Novel Observational Method for Assessing Acute Responses to Cannabis: Preliminary Validation Using Legal Market Strains |
title_fullStr | A Novel Observational Method for Assessing Acute Responses to Cannabis: Preliminary Validation Using Legal Market Strains |
title_full_unstemmed | A Novel Observational Method for Assessing Acute Responses to Cannabis: Preliminary Validation Using Legal Market Strains |
title_short | A Novel Observational Method for Assessing Acute Responses to Cannabis: Preliminary Validation Using Legal Market Strains |
title_sort | novel observational method for assessing acute responses to cannabis: preliminary validation using legal market strains |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870063/ https://www.ncbi.nlm.nih.gov/pubmed/29607409 http://dx.doi.org/10.1089/can.2017.0038 |
work_keys_str_mv | AT bidwelllcinnamon anovelobservationalmethodforassessingacuteresponsestocannabispreliminaryvalidationusinglegalmarketstrains AT muellerraeghan anovelobservationalmethodforassessingacuteresponsestocannabispreliminaryvalidationusinglegalmarketstrains AT yorkwilliamssophiel anovelobservationalmethodforassessingacuteresponsestocannabispreliminaryvalidationusinglegalmarketstrains AT hagertysarah anovelobservationalmethodforassessingacuteresponsestocannabispreliminaryvalidationusinglegalmarketstrains AT bryanangelad anovelobservationalmethodforassessingacuteresponsestocannabispreliminaryvalidationusinglegalmarketstrains AT hutchisonkente anovelobservationalmethodforassessingacuteresponsestocannabispreliminaryvalidationusinglegalmarketstrains AT bidwelllcinnamon novelobservationalmethodforassessingacuteresponsestocannabispreliminaryvalidationusinglegalmarketstrains AT muellerraeghan novelobservationalmethodforassessingacuteresponsestocannabispreliminaryvalidationusinglegalmarketstrains AT yorkwilliamssophiel novelobservationalmethodforassessingacuteresponsestocannabispreliminaryvalidationusinglegalmarketstrains AT hagertysarah novelobservationalmethodforassessingacuteresponsestocannabispreliminaryvalidationusinglegalmarketstrains AT bryanangelad novelobservationalmethodforassessingacuteresponsestocannabispreliminaryvalidationusinglegalmarketstrains AT hutchisonkente novelobservationalmethodforassessingacuteresponsestocannabispreliminaryvalidationusinglegalmarketstrains |